Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in relapsed or metastatic osteosarcoma
NCT03013127Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- May 2017
- Primary completion
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pembrolizumab in osteosarcoma (OS), sponsored by Oslo University Hospital. Started May 2017; status: terminated.
02
Drugs
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03013127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013127.